Agile Therapeutics Inc. announced the launch of the women’s healthcare company’s first consumer commercial intended to increase awareness of the Twirla weekly birth control patch.
With the Omicron surge waning – at least in the United States – there is speculation that the COVID-19 pandemic may be in its end stages, although some experts warn that this could be premature.
Astellas Pharma studied the potential of fezolinetant, a selective neurokinin-3 receptor (NK3R) antagonist, against hot flashes in a series of double-blinded and placebo-controlled trials.
Veru Inc. said a higher dose of the company’s experimental drug reduced hot flashes in men with advanced prostate cancer after six weeks of treatment, in a mid-stage study.